Joshua Cohen

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi request reprint Measuring progress in neglected disease drug development
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, Boston, Massachusetts Electronic address
    Clin Ther 36:1037-42. 2014
  2. ncbi request reprint Complying with state and deferral regulations on essential drug benefits: implementing the Affordable Care Act
    Joshua P Cohen
    Tufts Center for the Center of Drug Development, School of Medicine, 75 Kneeland St, Boston, MA 02111 E mail
    Am J Manag Care 20:153-8. 2014
  3. doi request reprint Clinical and economic challenges facing pharmacogenomics
    J Cohen
    Tufts University School of Medicine, Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Pharmacogenomics J 13:378-88. 2013
  4. doi request reprint Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs
    Joshua Cohen
    Center for the Study of Drug Development, Tufts University, Boston, MA, USA
    Health Aff (Millwood) 32:762-70. 2013
  5. doi request reprint Comparative-effectiveness research: does it matter?
    Joshua P Cohen
    Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Clin Ther 35:371-9. 2013
  6. ncbi request reprint Overcoming regulatory and economic challenges facing pharmacogenomics
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, United States
    N Biotechnol 29:751-6. 2012
  7. doi request reprint Evaluating the impact of Medicare Part D on quality metrics
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Expert Rev Pharmacoecon Outcomes Res 12:271-3. 2012
  8. doi request reprint Disease management and medication compliance
    Joshua Cohen
    Tufts Center for Study of Drug Development, Boston, Massachusetts 02111, USA
    Popul Health Manag 15:20-8. 2012
  9. ncbi request reprint Are Medicare plans complying with CMS regulation?
    Joshua Cohen
    Senior Research Fellow, Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Expert Rev Pharmacoecon Outcomes Res 8:133-9. 2008
  10. pmc Development of and access to products for neglected diseases
    Joshua Cohen
    Tufts University Center for the Study of Drug Development, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10610. 2010

Detail Information

Publications31

  1. ncbi request reprint Measuring progress in neglected disease drug development
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, Boston, Massachusetts Electronic address
    Clin Ther 36:1037-42. 2014
    ..Previous research showed modest gains in drug approvals and products in Phase III of clinical development in the period 2000-2008...
  2. ncbi request reprint Complying with state and deferral regulations on essential drug benefits: implementing the Affordable Care Act
    Joshua P Cohen
    Tufts Center for the Center of Drug Development, School of Medicine, 75 Kneeland St, Boston, MA 02111 E mail
    Am J Manag Care 20:153-8. 2014
    ..To examine health plan compliance with essential drug benefit regulations in California and Massachusetts and at the federal level...
  3. doi request reprint Clinical and economic challenges facing pharmacogenomics
    J Cohen
    Tufts University School of Medicine, Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Pharmacogenomics J 13:378-88. 2013
    ..An increase in comparative effectiveness research may help to close the evidence gap. ..
  4. doi request reprint Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs
    Joshua Cohen
    Center for the Study of Drug Development, Tufts University, Boston, MA, USA
    Health Aff (Millwood) 32:762-70. 2013
    ..The United States lacks a systematic approach to assessing such evidence in the coverage decision-making process, which may prove inadequate for controlling costs, improving outcomes, and reducing inequities in access to care...
  5. doi request reprint Comparative-effectiveness research: does it matter?
    Joshua P Cohen
    Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Clin Ther 35:371-9. 2013
    ..There has been less emphasis on implementation of CER findings, and examining whether CER has or will have an impact on prescribing patterns, reimbursement, health outcomes, and health care spending...
  6. ncbi request reprint Overcoming regulatory and economic challenges facing pharmacogenomics
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, United States
    N Biotechnol 29:751-6. 2012
    ....
  7. doi request reprint Evaluating the impact of Medicare Part D on quality metrics
    Joshua P Cohen
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Expert Rev Pharmacoecon Outcomes Res 12:271-3. 2012
    ..Priest and colleagues examine these claims and find suboptimal outcomes despite improved access...
  8. doi request reprint Disease management and medication compliance
    Joshua Cohen
    Tufts Center for Study of Drug Development, Boston, Massachusetts 02111, USA
    Popul Health Manag 15:20-8. 2012
    ....
  9. ncbi request reprint Are Medicare plans complying with CMS regulation?
    Joshua Cohen
    Senior Research Fellow, Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
    Expert Rev Pharmacoecon Outcomes Res 8:133-9. 2008
    ..Further research must be performed to determine whether, on balance, formulary exclusions and restrictions in these categories are harmful to patient outcomes...
  10. pmc Development of and access to products for neglected diseases
    Joshua Cohen
    Tufts University Center for the Study of Drug Development, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10610. 2010
    ....
  11. pmc New challenges to medicare beneficiary access to mAbs
    Joshua Cohen
    Tufts Center for the Study of Drug Development CSDD, Boston, Massachusetts 02111, USA
    MAbs 1:56-66. 2009
    ..We suggest more systematic use of "coverage with evidence development" as a means of optimally addressing these challenges...
  12. doi request reprint Follow-on drugs and indications: the importance of incremental innovation to medical practice
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Am J Ther 15:89-91. 2008
  13. ncbi request reprint State-based versus federal-based approaches to reducing the Medicare pharmaceutical coverage gap
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Int J Health Serv 33:345-58. 2003
    ..As a result, a more equitable distribution of prescription drug coverage would be promoted while mitigating the effects of selection risk...
  14. ncbi request reprint On the possibility of a positive-sum game in the distribution of health care resources
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University, 192 South St, Suite 550, Boston, MA 02111, USA
    J Med Philos 28:327-38. 2003
    ..However, in this paper it is shown that in a dynamic setting in which there are efficiency gains in the health production function, fairness in distribution of health care resources can improve simultaneously...
  15. ncbi request reprint The increasingly complex fourth hurdle for pharmaceuticals
    Joshua Cohen
    Tufts Center for Study of Drug Development, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 25:727-34. 2007
    ..It may be a matter of redeployment of resources across healthcare sectors, cancelling the funding of (older) pharmaceuticals that are less cost effective, or delisting drugs that are cost effective but target less burdensome conditions...
  16. ncbi request reprint Comment on: Should we really worry about "launch delays" of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Eur J Health Econ 8:169-70; discussion 171. 2007
  17. ncbi request reprint Patient access to pharmaceuticals: an international comparison
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Eur J Health Econ 8:253-66. 2007
    ..At the same time, our study confirms, qualitatively, different kinds of access problems in the US: relatively high patient cost sharing for pharmaceuticals, and wide variation in coverage...
  18. ncbi request reprint Switching omeprazole in Sweden and the United States
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Boston, Massachusetts 02111, USA
    Am J Ther 10:370-6. 2003
    ....
  19. ncbi request reprint Comparing patient access to pharmaceuticals in the UK and US
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Appl Health Econ Health Policy 5:177-87. 2006
    ..Additional barriers have since been identified. These pertain to reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles...
  20. ncbi request reprint Role of follow-on drugs and indications on the WHO Essential Drug List
    J Cohen
    Tufts Center for Study of Drug Development, Boston, MA 02111, USA
    J Clin Pharm Ther 31:585-92. 2006
    ..Critics suggest many follow-on drugs and indications offer little or no benefit to patients. Advocates counter that follow-on drugs offer advantages in terms of improved effectiveness, compliance and patient satisfaction...
  21. doi request reprint Transatlantic convergence with respect to the fourth hurdle?
    Joshua Cohen
    Tufts Center for Study of Drugs Development, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 24:87-94. 2006
    ..And these interests and values help shape how policy makers responsible for drug reimbursement in the US and Europe develop and apply the same types of evidence-based approaches differently...
  22. doi request reprint Patient access to new cancer drugs in the United States and Australia
    Andrew Wilson
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA
    Value Health 14:944-52. 2011
    ....
  23. ncbi request reprint Are clinical practice guidelines impartial?
    Joshua Cohen
    Erasmus University
    Int J Technol Assess Health Care 20:415-20. 2004
    ..To illustrate, I show how clinical practice guidelines are established and mediated by a reasonably partial expert panel whose partial action is publicly justifiable, yet whose claims to impartiality are not...
  24. pmc The empirical basis for determinations of medical futility
    Ezra Gabbay
    Division of Nephrology, Tufts Medical Center, Boston, MA 02111, USA
    J Gen Intern Med 25:1083-9. 2010
    ..Our objective was to systematically review the criteria for futility and the strength of empirical evidence across clinical studies that purport to support or refute claims of futility...
  25. ncbi request reprint Off-label use reimbursement
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA
    Food Drug Law J 64:391-403. 2009
    ..Furthermore, the survey data shed light on payer efforts to design off-label use reimbursement strategies, including the use of cost-effectiveness...
  26. doi request reprint Little evidence of correlation between growth in health care spending and reduced mortality
    Michael B Rothberg
    Tufts University School of Medicine, in Boston, Massachusetts, Baystate Medical Center, Springfield, Massachusetts, USA
    Health Aff (Millwood) 29:1523-31. 2010
    ..The message to be underscored once again for policy makers is that health care dollars provide inconsistent value, and future spending increases should be targeted to care that improves outcomes...
  27. doi request reprint What is the value of oncology medicines?
    Joshua Cohen
    Tufts University School of Medicine, Center for the Study of Drug Development, Boston, Massachusetts, USA
    Nat Biotechnol 28:1160-3. 2010
    ....
  28. pmc Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies
    Thomas W Concannon
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Circ Cardiovasc Qual Outcomes 3:506-13. 2010
    ..This study evaluated the comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies to increase the use of PCI against standard emergency transport and care...
  29. ncbi request reprint WHO: strengthening the road to renewal
    Joshua Cohen
    Lancet 368:450. 2006
  30. ncbi request reprint UNICEF: suggestions for change
    Joshua Cohen
    Lancet 365:291. 2005
  31. ncbi request reprint CEA is not a price control
    Joshua Cohen
    Health Aff (Millwood) 26:1505; author reply 1506-7. 2007